Pay in 4 interest-free payments of $6.14 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
Observed reductions in BP after 68 weeks of CagriSema treatment versus placebo were greater than those previously observed over the same time frame for semaglutide 2.4 mg in participants with overweight or obesity in the Semaglutide Treatment Effect in People with Obesity (STEP) 1, STEP 3, and STEP 4 trials, with an overall reduction in SBP versus placebo across the 3 trials of 5.0 (95% CI, 5.9 to 4.1) mm Hg
LISTEN | Are weight-loss drugs in Canada getting too easy to access?: A majority of those requests were from new patients, the company said in an emailed statement
The article says these warrant investigation for serious complications rather than self-management
Nature Chemistry 3:509524 Williams DM, et al (2024) Real-World clinical experience of oral semaglutide in a secondary diabetes clinic in the UK: a retrospective observational study
Despite this, NAD+ should not be viewed as a weight loss solution
-agonists-market-key-insight.png)
